Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Balachandran’s work could “transform the treatment of pancreatic cancer…and provide proof of concept for future cancer vaccines.”
Companies announced the start of a Phase III trial that will enroll more than 1,000 people with high-risk melanoma.
Biden’s CUREIT initiative aims to develop a toolbox of technologies to fight cancer, autoimmune disorders and infectious diseases.
A personalized melanoma vaccine enters a Phase III study, while a pancreatic cancer vaccine moves on to Phase II.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
A personalized neoantigen vaccine from BioNTech and Roche/Genentech lowered the risk of relapse after surgery.
Research reinforces recommendations from the American Cancer Society and American Academy of Pediatrics to start HPV vaccines at a young age
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
The BNT111-01 clinical trial explores an mRNA melanoma vaccine on its own and in combination with a PD-1 checkpoint immunotherapy.
The experimental vaccine trains the immune system to recognize HER2 proteins on breast tumors.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
NIH study finds therapeutic vaccine administered via IV infusion improves tumor-fighting T-cell action in mice.
The technology used to create COVID-19 vaccines may also help treat cancer.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
The success of the mRNA COVID-19 vaccines could help accelerate clinical research on vaccines to treat cancer.
A novel clinical trial based on research from Cleveland Clinic’s Lerner Research Institute targets triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.